Antimicrobial switch therapy

Connecticut Medicine

Volumn 62, Issue 11, 1998, Pages 665-668

  Bui, Khanh ^a   Quintiliani, Richard ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; CEFALEXIN; CEFAZOLIN; CEFEPIME; CEFIXIME; CEFOTAXIME; CEFOTETAN; CEFPODOXIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TROVAFLOXACIN;

ABDOMINAL INFECTION; ANTIBIOTIC THERAPY; BACTERIAL INFECTION; HOSPITAL INFECTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PNEUMONIA; PRACTICE GUIDELINE; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION;

ADMINISTRATION, ORAL; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BONE DISEASES, INFECTIOUS; CLINICAL PROTOCOLS; CROSS INFECTION; DOSAGE FORMS; DRUG ADMINISTRATION ROUTES; DRUG COSTS; ECONOMICS, HOSPITAL; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; LENGTH OF STAY; MALE; PNEUMONIA; SKIN DISEASES, INFECTIOUS; SOFT TISSUE INFECTIONS;

EID: 0032406706     PISSN: 00106178     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (11)

1. Quintiliani R, Cooper BW, Nightingale CH: Economic impact on streamlining antibiotic admininstration. Am J Med 1987; 82: 391-4.
2. Hendrickson JR, North DS:. Pharmacoeconomic benefit of antibiotic step-down therapy: Converting patients from intravenous ceftriaxone to oral cefpodoxime proxetil. Ann Pharmacother 1995; 29:561-5.
3. Ramirez JA, Srinath L, Ahkee S, et al: Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155:1273-6.
4. Cassiere HA, Fein AM: Duration and route of antibiotic therapy in community-acquired pneumonia: Switch and step-down therapy. Semin Resp Infect 1998; 13:36-42.
5. Quintiliani R, Nightingale CH, Nicolau DP, Ambrose PG: Hartford Hospital Transitional Antibiotic Program 1998 (7th ed).
6. Fish DN, Chow AT: The clinical pharmacokinetics and safety of levofloxacin. Clin Pharmacokinet 1997; 32:101-19.
7. Teng R, Liston TE, Harris SC: Multiple-dose pharmacokinetics and safety of trovafloxacin in healthy volunteers. J Antimicrob Chemother 1996; 37:955-63.
8. Shimada J, Nogita T, Ishibashi Y: Clinical pharmacokinetics of sparfloxacin. Clin Pharmacokinet 1993; 25:358-69.
9. Child J, Andrews JM, Wise R: Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin. Antimicrob Agents Chemother 1995; 39:513-5.
10. Arnow PM, Quimosing EM, Beach M: Consequences of intravascular catheter sepsis. Clin Infect Dis 1993; 16:778-84.
11. Quintiliani R, Crowe HM, Nightingale C: Transitional antibiotic therapy. Can J Infect Dis 1995;6(Suppl A):6A-10A.